Latest Information Update: 09 Jul 2002
At a glance
- Originator Bayer
- Class Antiasthmatics
- Mechanism of Action Metalloprotease inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 15 Mar 2000 New profile
- 15 Mar 2000 Phase-I clinical trials for Chronic obstructive pulmonary disease (Unknown route)
- 15 Mar 2000 Phase-I clinical trials for Asthma (Unknown route)